Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
  • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the invention relates to substituted S-phenyl- ⁇ -alkoxy-I .S ⁇ -oxadiazole- ⁇ -ones which have an inhibitory effect on the pancreatic lipase, PL.
• Certain 5-alkoxy-1, 3,4-oxadiazol-2-ones with an ortho-substituted phenyl ring as substituents or with fused five- or six-membered rings have anthelmintic (DE-A 26 04 110) and insecticidal action (DE-A 26 03 877, EP-B 0 048 040, EP-B 0 067471).
• the aim of the invention was therefore to find compounds which show an inhibitory effect on the pancreatic lipase, PL.
• R 1 is C 7 -C 22 alkyl; by C 4 -C 2 -alkoxy, C 6 -C 10 aryl, C 6 -aryloxy or C 4 0 -C ⁇ -C ⁇ 2 -
• C 1 -C 4 -alkyl, C -C -alkyloxy, nitro or CF 3 may be mono- or polysubstituted phenyl or naphthyl; C 2 -C 20 alkenyl; 3.beta.-cholestan-3-yl; by
• R 2 , R 3 , R 4 and R 5 independently of one another are hydrogen, halogen, nitro, C 1 -C 4 -alkyl,
• C 4 alkyl may be monosubstituted, disubstituted or trisubstituted
• aryl radicals may optionally be mono- or polysubstituted by C 1 -C -alkyl, C 1 -C -alkyloxy, halogen, trifluoromethyl.
• the cycloalkyl radicals mentioned may optionally be monosubstituted or polysubstituted by C 1 -C 4 -alkyl, C 1 -C 10 -aryl and the abovementioned alkyl radicals may be substituted by hydroxyl, C 1 -C 4 -alkylamino and fluorine.
• Halogen is fluorine, chlorine, bromine, preferably fluorine and chlorine.
• Alkyl, alkenyl, alkoxy, etc. may be branched or unbranched.
• Preferred compounds is of formula 1 wherein R 1 is C 7 -C 22 alkyl, C 7 -C 2 o-alkenyl, 3ß- cholestane-3-yl or C 6 -C 2 alkyl substituted by phenoxy or phenyl.
• R 2 is hydrogen, halogen, CC 4 -alkyl or C 1 -C 6 -alkyloxy; and / or R 3 is hydrogen, C 1 -C 4 -alkyl, trifluoromethoxy, C 6 -C 10 -aryl-C 1 -C -alkyloxy, which may optionally be substituted by halogen in the aryl moiety; and or R 4 is hydrogen, trifluoromethoxy or chlorophenoxy; and or
• R 5 is hydrogen
• R 1 is C 8 -C 16 -alkyl
• R 2 is hydrogen
• R 3 is hydrogen or trifluoromethyloxy
• R 4 is hydrogen, trifluoromethyloxy or 4-chlorophenoxy and R 5 is hydrogen.
• the compounds of the general formula 1 according to the invention have an inhibiting effect on the pancreatic lipase, PL.
• the invention relates to the compounds of formula 1, in the form of their racemates, racemic mixtures and pure enantiomers, and to their diastereomers and mixtures thereof.
• Suitable pharmaceutically acceptable acid addition salts of the compounds of formula 1 are salts of inorganic acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfamic and sulfuric and organic acids such as acetic acid, benzenesulfonic, benzoic, citric, Ethane sulfone, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic, tartaric and trihydric fluorine acetic acid.
• inorganic acids such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric, sulfamic and sulfuric and organic acids such as acetic acid, benzenesulfonic, benzoic, citric, Ethane sulfone, fumaric, gluconic, glycolic, isethionic,
• Suitable pharmaceutically acceptable basic salts are ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth salts (such as magnesium and calcium salts).
• Salts with a non-pharmaceutically acceptable anion are also within the scope of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and / or for use in nontherapeutic, for example, in vitro applications.
• physiologically functional derivative refers to any physiologically acceptable derivative of a compound of the invention, e.g. an ester which, when administered to a mammal, e.g. humans, is able to form (directly or indirectly) such a compound or an active metabolite thereof.
• prodrugs of the compounds of formula 1 may be metabolized in vivo to a compound of formula 1. These prodrugs may or may not be effective.
• the compounds of formula 1 may also be in various polymorphic forms, e.g. as amorphous and crystalline polymorphic forms. All polymorphic forms of the compounds of formula 1 are within the scope of the invention and are a further aspect of the invention.
• the amount of a compound of Formula 1 required to achieve the desired biological effect is dependent upon a number of factors, eg, the specific compound chosen, the intended one Use, the mode of administration and the clinical condition of the patient.
• the daily dose ranges from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day per kilogram of body weight, eg, 3-10 mg / kg / day.
• an intravenous dose may range from 0.3 mg to 1.0 mg / kg, which may suitably be administered as an infusion of 10 ng to 100 ng per kilogram per minute.
• Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg per milliliter.
• Single doses may contain, for example, from 1 mg to 10 g of the active ingredient.
• vials for injections, and orally administrable unit dose formulations, such as tablets or capsules may contain, for example, from 1.0 to 1000 mg, typically from 10 to 600 mg.
• the abovementioned weights are based on the weight of the salt of the compound of the formula 1.
• the compounds according to formula 1 itself can be used as a compound, but are preferably in an acceptable carrier Form of a pharmaceutical composition.
• the carrier must of course be compatible in the sense that it is compatible with the other ingredients of the composition and is not harmful to the patient.
• the carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a single dose, for example, as a tablet, which may contain from 0.05% to 95% by weight of the active ingredient.
• Other pharmaceutically active substances may also be present, including further compounds according to formula 1.
• the pharmaceutical compositions according to the invention can be prepared by one of the known pharmaceutical methods, which consist essentially in that the ingredients are mixed with pharmacologically acceptable carriers and / or excipients ,
• compositions according to the invention are those which are suitable for oral, rectal, topical, peroral (eg sublingual) and parenteral (eg subcutaneous, intramuscular, intradermal or intravenous) administration, although the most suitable mode of administration in each individual case of the type and Severity of the condition to be treated and on the nature of the particular compound used in accordance with formula 1 is dependent.
• coated formulations and coated slow release formulations are within the scope of the invention.
• Suitable pharmaceutical compounds for oral administration may be in separate units, such as capsules, cachets,
• Lozenges or tablets each containing a certain amount of the compound of formula 1; as a powder or granules; as a solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion.
• these compositions may be prepared by any suitable pharmaceutical method comprising a step of contacting the active ingredient and the carrier (which may consist of one or more additional ingredients).
• the compositions are prepared by uniformly and homogeneously mixing the active ingredient with a liquid and / or finely divided solid carrier, after which the product is molded, if necessary.
• a tablet can be made by compressing or molding a powder or granules of the compound, optionally with one or more additional ingredients.
• Pressed tablets may be prepared by tableting the compound in free-flowing form, such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent and / or surfactant / dispersant in a suitable machine.
• Molded tablets may be prepared by shaping the powdered compound moistened with an inert liquid diluent in a suitable machine.
• compositions suitable for peroral (sublingual) administration include lozenges comprising a compound according to Formula 1 with a flavorant, usually sucrose and gum arabic or tragacanth, and lozenges comprising the compound in an inert base such as gelatin and glycerine or sucrose and gum arabic.
• Suitable pharmaceutical compositions for parenteral administration preferably comprise sterile aqueous preparations of a compound according to formula 1 which are preferably isotonic with the blood of the intended recipient. These preparations are preferably administered intravenously, although the administration may also be subcutaneous, intramuscular or intradermal as an injection. These preparations may preferably be prepared by mixing the compound with water and rendering the resulting solution sterile and isotonic with the blood. Injectable compositions of the invention generally contain from 0.1% to 5% by weight of the active compound.
• Suitable pharmaceutical compositions for rectal administration are preferably as single dose suppositories. These can be prepared by mixing a compound according to formula 1 with one or more conventional solid carriers, for example cocoa butter, and shaping the resulting mixture.
• Suitable pharmaceutical compositions for topical application to the skin are preferably as an ointment, cream, lotion, paste, spray, aerosol or oil.
• Vaseline, lanolin, polyethylene glycols, alcohols, and combinations of two or more of these substances can be used as the carrier.
• the active ingredient is generally present at a level of from 0.1% to 15% by weight of the composition, for example from 0.5% to 2%.
• Suitable pharmaceutical compositions for transdermal applications may exist as single patches suitable for long-term close contact with the epidermis of the patient. Such patches suitably contain the active ingredient in an optionally buffered aqueous solution, dissolved and / or dispersed in one Adhesive or dispersed in a polymer.
• a suitable active ingredient concentration is about 1% to 35%, preferably about 3% to 15%.
• the active ingredient can be released by electrotransport or iontophoresis as described, for example, in Pharmaceutical Research, 2 (6): 318 (1986).
• the hydrazines of the formula 2 can be prepared by known methods, for example by diazotization of the corresponding anilines and
• Phenyldehvaten 6 F, Cl, Br, I, OSO 2 CF 3
• suitable phenyl derivatives may be nitro-substituted halobenzenes, preferably fluoro- and chloro-nitrobenzenes, from which at a suitable point in the synthetic route by reduction and reaction with acylating or alkylating agents, such as acid chlorides, anhydrides, isocyanates, chloroformates, sulfonyl chlorides or alkyl and Arylalkyl ⁇ halides, or can be prepared by reductive alkylation with aldehydes by known methods, the compounds of the invention.
• the compounds of formula 1 show an inhibitory effect on pancreatic lipase (PL). As inhibitors of PL, they can prevent the resorption of the fat ingested with food and thereby reduce the Fat intake and body weight or prevent an increase in body weight.
• the compounds of formula 1 are particularly useful in the treatment of obesity, but may also exert a very favorable influence on various derailments of the metabolism, such as diabetes, of the cardiovascular system, such as hypertension and myocardial infarction.
• 80 ul tripalmitin (85 mM in chloroform) are mixed with 5 ul Glyzerintri [9,10 (n) - 3 H] oleate mixed (5 mCi / ml in toluene) in a 12 ml polypropylene vessel. After rotation (50 ° C.) and addition of 4 ml 200 mM Tris / HCl (pH 7.6), 0.8% TX-100, the mixture is treated with ultrasound (Branson Sonifier B-12, power level 4, 3 times 2 min. min intervals on ice) until a homogeneous milky cloudy suspension is formed.
• ultrasound Branson Sonifier B-12, power level 4, 3 times 2 min. min intervals on ice
• Lipase buffer 80 mM Tris / HCl (pH 7.6), 600 mM NaCl, 8 mM CaCl 2 , 8 mM benzamidine, 2 mM Pefabloc (Roche Biochemicals) (add inhibitors only on the test day)
• Pancreatic lipase enriched preparation from porcine pancreas (Sigma order no. L-0382) dissolved in lipase buffer (100,000 units / 500 ⁇ l)
• Example 4 5-Hexadecyloxy-3- (3-trifluoromethoxy-phenyl) -3H- (1, 3,4) -oxadiazol-2-one M.p .: 53 ° C
• Example 5 5-Hexadecyloxy-3- (3-trifluoromethoxy-phenyl) -3H- (1, 3,4) -oxadiazol-2-one M.p .: 53 ° C
• Example 5 Example 5:
• Example 12 5-Hexadecyloxy-3- (4-methoxy-phenyl) -3H- (1, 3,4) -oxadiazol-2-one M.p .: 66 ° C
• Example 13 5-Hexadecyloxy-3- (4-methoxy-phenyl) -3H- (1, 3,4) -oxadiazol-2-one M.p .: 66 ° C
• Example 13 5-Hexadecyloxy-3- (4-methoxy-phenyl) -3H- (1, 3,4) -oxadiazol-2-one M.p .: 66 ° C
• Example 13 Example 13:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Diabetes (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Child & Adolescent Psychology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Steroid Compounds (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=27740558

Family Applications (1)

Country Status (22)

Cited By (4)

Citations (2)

• 2002
  • 2002-02-28 DE DE10208987A patent/DE10208987A1/de not_active Withdrawn
• 2003
  • 2003-02-05 PE PE2003000134A patent/PE20030928A1/es not_active Application Discontinuation
  • 2003-02-14 HR HR20040782A patent/HRP20040782A2/hr not_active Application Discontinuation
  • 2003-02-14 AT AT03742936T patent/ATE557012T1/de active
  • 2003-02-14 AU AU2003226977A patent/AU2003226977A1/en not_active Abandoned
  • 2003-02-14 WO PCT/EP2003/001484 patent/WO2003072555A1/de not_active Ceased
  • 2003-02-14 JP JP2003571261A patent/JP4486363B2/ja not_active Expired - Fee Related
  • 2003-02-14 MX MXPA04007960A patent/MXPA04007960A/es unknown
  • 2003-02-14 EP EP03742936A patent/EP1480960B1/de not_active Expired - Lifetime
  • 2003-02-14 CN CNA038047837A patent/CN1639137A/zh active Pending
  • 2003-02-14 KR KR10-2004-7013485A patent/KR20040095240A/ko not_active Withdrawn
  • 2003-02-14 IL IL16368303A patent/IL163683A0/xx unknown
  • 2003-02-14 PL PL03370423A patent/PL370423A1/xx not_active Application Discontinuation
  • 2003-02-14 HU HU0402671A patent/HUP0402671A3/hu unknown
  • 2003-02-14 CA CA002477031A patent/CA2477031A1/en not_active Abandoned
  • 2003-02-14 BR BR0307921-0A patent/BR0307921A/pt not_active Application Discontinuation
  • 2003-02-14 RU RU2004128933/04A patent/RU2004128933A/ru not_active Application Discontinuation
  • 2003-02-26 TW TW092103969A patent/TW200400951A/zh unknown
  • 2003-02-26 AR ARP030100624A patent/AR038701A1/es unknown
• 2004
  • 2004-07-27 MA MA27803A patent/MA27172A1/fr unknown
  • 2004-08-26 CO CO04083779A patent/CO5611146A2/es not_active Application Discontinuation
  • 2004-09-27 NO NO20044090A patent/NO20044090L/no not_active Application Discontinuation

Patent Citations (2)

Also Published As

Similar Documents

Legal Events